U.S. Market for Cardiovascular Devices, The

U.S. Market for Cardiovascular Devices, The

CHAPTER ONE: Executive Summary

Background
Cardiomyopathy/Congestive Heart Failure
Left Ventricular (LV) Failure
Right Ventricular (RV) Failure
Systolic Dysfunction
Diastolic Dysfunction
High Output Failure


Arrhythmias
Arteriosclerosis (Coronary Artery Disease)
Heart Valve Disease
Scope and Methodology
Size and Growth of Market
Competitive Picture
Market Trends and Factors


CHAPTER TWO: Overview of Cardiovascular Disease

Background
Aneurysm
Arrhythmias
Athletic Heart Syndrome
Cardiac Arrest
Cardiac Tumors
Cardiomyopathy
Congenital Heart Disease
Congestive Heart Failure
Types of Heart Failure
Left Ventricular (LV) Failure
Right Ventricular (RV) Failure
Systolic Dysfunction
Diastolic Dysfunction
High Output Failure
Theories of Heart Failure
Hemodynamic Response Theory
Neurohormonal Response Theory
Renal Response Theory


Coronary Artery Disease
Endocarditis
Infective Endocarditis
Subacute bacterial endocarditis (SBE)
Acute bacterial endocarditis (ABE)
Prosthetic valvular endocarditis
Right-sided endocarditis
Noninfective Endocarditis


Hypertension/Hypotension
Pericardial Disease
Shock
Hypovolemic shock
Vasodilatory shock
Cardiogenic shock


Valvular Heart Disease
Vascular Disease


CHAPTER THREE: Demographics and Epidemiology


Background
Population Demographics
Epidemiology and Pathology of Cardiovascular Diseases
Cardiomyopathy/Congestive Heart Failure (CHF)
Types of Heart Failure
Left Ventricular (LV) Failure
Right Ventricular (RV) Failure
Systolic Dysfunction
Diastolic Dysfunction
High Output Failure
Theories of Congestive Heart Failure
Hemodynamic Response Theory
Neurohormonal Response Theory
Renal Response Theory
Conditions Leading to Congestive Heart Failure


Arrhythmias
Arteriosclerosis/Atherosclerosis
Heart Valve Disease


CHAPTER FOUR: Therapeutic Cardiovascular Devices


Overview
Prosthetic Heart Valves
Pacemakers
Implantable Cardioverter-Defibrillators (ICDs)
Ventricular Assist Devices (VADs)
Total Artificial Heart Devices (TAHs)
Coronary Artery Stents
Cardiac Support Devices


CHAPTER FIVE: Market Analysis


Market Size and Growth Overview
Cardiomyopathy/Congestive Heart Failure (CHF)
Arrhythmia
Arteriosclerosis
Heart Valve Diseases


The 45+-Year-Old Market: A General View
Cardiomyopathy/Congestive Heart Failure
Arrhythmias
Arteriosclerosis
Valvular Heart Disease


Competitive Outlook
Market Trends


CHAPTER SIX: Company Profiles


Overview
Abbott Vascular Devices Division of Abbott Laboratories
Abiomed, Inc.
Acorn Cardiovascular, Inc.
Arrow International
Boston Scientific Corp.
Cordis Corporation (A Johnson & Johnson Company)
Guidant Corporation A Johnson & Johnson Company
Medtronic, Inc.
Cardiac Rhythm Management (CRM)
Vascular
Cardiac Surgery
MicroMed Technology, Inc.
Myocor, Inc.
St. Jude Medical
Somanetics Corporation
Somanetics Corporation
Thoratec Corporation


Chapter Seven: Conclusions and Strategic Implications

First Conclusion
Implications:
Second Conclusion
Implications:
Third Conclusion
Implications:
Fourth Conclusion
Implications:
Fifth Conclusion
Implications:
Sixth Conclusion
Implications:
Seventh Conclusion
Implications:
Eighth Conclusion
Implications:
Ninth Conclusion
Implications:
Tenth Conclusion
Implications:
Eleventh Conclusion
Implications:
Twelfth Conclusion
Implications:
Thirteenth Conclusion
Implications:

 
APPENDIX A: Company Directory


APPENDIX B: Glossary


List of Exhibits

CHAPTER ONE: Executive Summary
Table 1-1: Prevalence of Selected Cardiovascular Diseases in the United States for the Total Population and Those 45 Years of Age and Older 2004-2014
Figure 1-1: Trending in United States Cardiovascular Disease Prevalence in the General Population and the 45+ Year Old Age Group 2004 - 2014
Figure 1-2: Trending in U.S. Cases of Cardiomyopathy/Congestive Heart Failure 2004-2014
Figure 1-3: Trending in U.S. Cases of Arrhythmia 2004-2014
Figure 1-4: Trending in United States Cases of Arteriosclerosis (Coronary Artery Disease): 2004-2014
Figure 1-5: Trending in U.S. Cases of Valvular Heart Disease 2004-2014
Table 1-2: The Projected U.S. Total Available Market Potential of Therapeutic Devices for Cardiovascular Diseases by Type (Congestive Heart Failure, Arrhythmia, Arteriosclerosis and Heart Valve Disease) in the General Population and the Population Aged 45 Years and Older 2004-2014
Figure 1-6: The Projected U.S. Total Available Market Potential of Therapeutic Devices for Cardiovascular Diseases in the General Population and the Population Aged 45 Years and Older 2004-2014
Table 1-3: Key Competitors in the Therapeutic Cardiovascular Device Markets


CHAPTER tWO: Overview of Cardiovascular Disease
Table 2-1: Benign and Malignant Cardiac Tumors
Table 2-2: Common Contributors to Congestive Heart Failure


CHAPTER THREE: Demographics and Epidemiology
Figure 3-1: Growth of the World’s Elderly (60+ Years) Population 2001 - 2025
Figure 3-2: Population Distribution of the United States by Age and Sex for 2000, 2005 and 2010
Figure 3-3: The Growing United States Population: 2004-2014
Figure 3-4: Projected Increasing Median Age of the United States Population: 2004-2014
Figure 3-5: Projected Increasing Mean Age of the United States Population: 2004-2014
Table 3-1: Prevalence of Selected Cardiovascular Diseases (CVD) in the United States for the Total Population and Those 45 Years of Age and Older: 2004 - 2014
Figure 3-6: Trending in United States Selected Cardiovascular Disease (CVD) Cases in the General Population and the 45+ Year Old Age Group: 2004 - 2014
Table 3-2: Prevalence Statistics for Different Types of Cardiomyopathy in the United States
Table 3-3: Common Contributors to Congestive Heart Failure
Table 3-7: Trending in the Prevalence of Cardiomyopathy/Congestive Heart Failure in the United States (Total Population and Those Aged 45 Year and Older) 2004-2014
Table 3-4: Types of Arrhythmias
Table 3-5: Prevalence Statistics for Types of Arrhythmias in the United States (22 types)
Table 3-8: Trending in the Prevalence of Arrhythmia in the United States (Total Population and Those Aged 45 Year and Older) 2004-2014
Table 3-9: Trending in the Prevalence of Arteriosclerosis (CAD) in the United States (Total Population and Those Aged 45 Year and Older) 2004-2014
Table 3-10: Trending in the Prevalence of Heart Valve Disease in the United States (Total Population and Those Aged 45 Year and Older) 2004-2014

 
CHAPTER FOUR: Therapeutic Cardiovascular Devices
Table 4-1: Key Providers of Prosthetic Heart Valves
Table 4-2: Key Providers of Pacemakers
Table 4-3: Key Providers of ICDs
Table 4-4: Key Providers of VADs
Table 4-5: Key Providers of TAHs
Table 4-6: Candidate Drugs for Drug-Eluting Stents
Table 4-7: Companies Active in Drug-Eluting Stent Commercialization
Table 4-8: Key Providers of Cardiac Support Devices


CHAPTER FIVE: Market Analysis
Table 4-1: The Projected U.S. Total Available Market Potential for Therapeutic Devices by Condition (Arteriosclerosis, Cardiomyopathy/Congestive Heart Failure, Arrhythmia and Heart Valve Disease) 2004-2014
Figure 4-1: Trending in the Projected U.S. Total Available Market Potential Therapeutic Devices by Condition (Arteriosclerosis, Cardiomyopathy/Congestive Heart Failure, Arrhythmia and Heart Valve Disease) 2004-2014
Figure 4-2: Trending in the Projected U.S. Total Available Market Potential for Therapeutic Cardiovascular Devices Used for the Treatment of Cardiomyopathy/Congestive Heart Failure 2004-2014
Figure 4-3: Trending in the Projected U.S. Total Available Market Potential for Therapeutic Cardiovascular Devices in the Treatment of Arrhythmias 2004-2014
Figure 4-4: Trending in the Projected U.S. Total Available Market Potential for the Therapeutic Cardiovascular Devices in the Treatment of Arteriosclerosis 2004-2014
Figure 4-5: Trending in the Projected U.S. Total Available Market Potential for Therapeutic Cardiovascular Devices in the Treatment of Heart Valve Diseases 2004-2014
Table 4-2: The Projected U.S. Total Available Market Potential for Therapeutic Devices in the 45+ Year Old Age Group by Condition (Arteriosclerosis, Cardiomyopathy/Congestive Heart Failure, Arrhythmia, and Heart Valve Disease) 2004-2014
Figure 4-6: Trending in the Projected U.S. Total Available Market Potential for Therapeutic Devices in the 45+ Year Old Age Group by Condition (Arteriosclerosis, Cardiomyopathy/Congestive Heart Failure, Arrhythmia, and Heart Valve Disease) 2004-2014
Figure 4-7: Trending in the Projected U.S. Total Available Market Potential for Therapeutic Cardiovascular Devices in the Treatment of Cardiomyopathy/Congestive Heart Failure in the 45+-Year-Old Population 2004-2014
Figure 4-8: Trending in the Projected U.S. Total Available Market Potential for Therapeutic Cardiovascular Devices in the Treatment of Arrhythmias in the 45+-Year-Old Population 2004-2014
Figure 4-9: Trending in the Projected U.S. Total Available Market Potential for Therapeutic Cardiovascular Devices in the Treatment of Arteriosclerosis in the 45+-Year-Old Population 2004-2014
Figure 4-10: Trending in the Projected U.S. Total Available Market Potential for Therapeutic Cardiovascular Devices in the Treatment of Heart Valve Disease in the 45+-Year-Old Population 2004-2014